Discussion of the controversies associated with prostate cancer screening.
Early detection of prostate cancer through screening seems to provide the best hope of control or possibly cure of the disease. Unfortunately, controversy and confusion surround the screening guidelines. Specifically, the controversy involves whether the screening of asymptomatic men, particularly those under age 50, should be recommended. To date, there have been no randomised clinical trials which have demonstrated that screening for prostate cancer reduces mortality or increases life expectancy. The lack of evidence regarding the benefits of prostate screening and the risk of adverse effects make it important for clinicians to provide information to interested patients regarding the possible consequences before they take part in screening endeavours. Other health care professionals must be proactive in becoming informed about the entire prostate screening issue.
Wolfe
E S
ES
Medical College of Ohio, School of Nursing, Toledo 43699-0008, USA.
Wolfe
W W
WW
D000368:Aged; D003362:Cost-Benefit Analysis; D006801:Humans; D007258:Informed Consent; D008297:Male; D008403:Mass Screening / Q000191:economics; D008875:Middle Aged; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D012680:Sensitivity and Specificity; D014481:United States / Q000453:epidemiology